Howard L. Petterson

The recent declaration from the Food and Drug Administration (FDA) concerning non-approved thyroid treatments has led to a complicated and sometimes inconsistent scenario for both patients and medical professionals. The agency has issued a significant alert about the potential safety hazards linked to these medications, particularly a type of "animal-derived thyroid" (ADT) products. At the same time, the FDA has expressed its plan to "maintain accessibility" to these exact medications, at least for a temporary phase. This dual communication highlights the fragile equilibrium the FDA must maintain between its duty to safeguard public health and its obligation to avoid disrupting…

A recent study suggests that incorporating just 3,000 steps a day at a brisk pace could significantly reduce the risk of developing cardiovascular disease. The research highlights the importance of not just the quantity of steps but also their intensity. This finding provides a powerful, actionable insight for individuals looking to improve their heart health without committing to an extensive or time-consuming exercise regimen. It reinforces the idea that even moderate, consistent physical activity can yield substantial health benefits.The research, which evaluated data from many participants, concentrated on the link between the number of steps taken each day, the pace…

A growing body of research suggests that individuals may exhibit subtle symptoms of multiple sclerosis (MS) long before they receive a formal diagnosis. These early, often-overlooked signs are now a key focus for researchers aiming to improve the timeline for detection and treatment. By identifying these preclinical indicators, medical professionals hope to intervene earlier, potentially slowing the progression of the disease and improving long-term patient outcomes. This shift in focus from managing the disease after onset to understanding its earliest phases marks a significant advance in MS research.Esta fase temprana, a menudo llamada fase prodrómica, tiende a presentar síntomas inespecíficos…

A growing trend in the use of GLP-1 receptor agonists for weight loss involves a practice known as "microdosing." This experimental approach, which entails taking a lower-than-prescribed dose of these popular medications, is being adopted by some patients in an attempt to manage side effects, reduce costs, or achieve more gradual weight loss. However, this strategy is not without significant debate, and medical professionals are carefully weighing the potential benefits against a number of substantial risks.The appeal of microdosing is primarily driven by a desire to mitigate the common, and often severe, gastrointestinal side effects associated with the standard therapeutic…